Literature DB >> 14646534

Apoptotic index, Fas and bcl-2 in initial and relapsed childhood acute lymphoblastic leukaemia.

G Stammler1, A Sauerbrey, F Zintl, M Volm.   

Abstract

Seventy-two samples with initial and 23 samples with relapsed childhood acute lymphoblastic leukaemia (ALL) were investigated for apoptotic index (AI) and for Fas expression. AI was determined by DNA-fragmentation using deoxynucleotidyl terminal transferase and Fas expression by immunocytochemistry. bcl-2 mRNA expression was measured in 50 initial and 20 relapsed ALL. The patients were discriminated in groups with low and high AI, Fas-protein expression and bcl-2mRNA expression by the mean value. AI was higher in relapsed than in initial ALL. The mean survival was significantly higher in patients with low AI (p= 0.034). This was also true for the relapse-free interval, however, this result was borderline significant (p= 0.064). AI was directly correlated with expression of Fas and inversely correlated with bcl-2 mRNA expression. These results suggest that Fas and - with limitations - bcl-2 may influence the apoptotic process in childhood ALL and that enhanced apoptotic activity predicts poor prognosis.

Entities:  

Year:  1997        PMID: 14646534     DOI: 10.1023/a:1026405707823

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  3 in total

Review 1.  Tumor immunotherapy: lessons from autoimmunity.

Authors:  Christian Maueröder; Luis Enrique Munoz; Ricardo Alfredo Chaurio; Martin Herrmann; Georg Schett; Christian Berens
Journal:  Front Immunol       Date:  2014-05-13       Impact factor: 7.561

2.  Proliferation index: a continuous model to predict prognosis in patients with tumours of the Ewing's sarcoma family.

Authors:  Samantha Brownhill; Dena Cohen; Sue Burchill
Journal:  PLoS One       Date:  2014-08-26       Impact factor: 3.240

Review 3.  Apoptotic Tumor Cell-Derived Extracellular Vesicles as Important Regulators of the Onco-Regenerative Niche.

Authors:  Christopher D Gregory; Ian Dransfield
Journal:  Front Immunol       Date:  2018-05-23       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.